Robot-aided heart valve surgery takes a step forward with CardioPrecision's groundbreaking announcement.
In a major breakthrough for cardiovascular care, Glasgow-based company CardioPrecision has successfully executed the world's first successful robot-assisted transcervical aortic valve replacement (AVR) procedure. This pioneering procedure was performed at the internationally renowned Cleveland Clinic in August 2025.
Key clinical and technical points include:
- The CoreVista® Retractor System, a key component of CardioPrecision's CoreVista® Robot Enabling Platform, allows access to the aortic valve through a small incision in the neck, minimising trauma compared to traditional open-heart surgery.
- The transcervical approach offers less pain, quicker recovery, and shorter hospital stays, potentially making it one of the least invasive surgical options for aortic valve replacement.
- The Perceval Plus sutureless valve, designed to integrate well with robotic surgery, was used successfully during the first case, showcasing compatibility between CardioPrecision's robotic platform and advanced valve technology.
- Surgeons report that the procedure becomes easier with experience, with ongoing goals to enhance its efficiency and reproducibility by improving steps like optimal port placement and reducing cross-clamp times.
- The technology reflects a broader trend toward robotic-assisted heart surgery, aiming to extend robotics' benefits—already common in other surgical fields—to cardiac patients.
CardioPrecision's vision of totally endoscopic cardiac surgery via the neck, originally supported by Scotland’s innovation sector, has now translated into tangible results with clinical deployment. The company's vision is to have every cardiac surgeon offering the robotic-assisted aortic valve replacement procedure to their patients.
Ongoing efforts include expanding training, refining protocols, and collaborations with other medical centers like the University of Chicago, aiming to standardise this technique for wider use in cardiac surgery.
This latest development is a significant advancement in the field of cardiac surgery, offering a minimally invasive alternative for patients with aortic valve disease. With positive clinical indications of safety, reduced invasiveness, and patient recovery benefits, CardioPrecision's robotic AVR procedure is poised to revolutionise the approach to cardiac surgery.
[1] CardioPrecision Press Release, August 2025 [2] Ying Sutherland, PhD, Chief Executive Officer of CardioPrecision [3] Dr. Marijan Koprivanac, Surgeon Involved in the Procedure [4] Graham Watson, Executive Chair of InnoScot Health [5] US News and World Report, Top Heart Hospital Rankings, 2025
- This robot-assisted transcervical aortic valve replacement procedure, a significant advancement in cardiovascular health, is seen as part of a broader science and technology trend towards digital health and medical-condition treatment, with CardioPrecision's vision being to make this technology accessible for all cardiac surgeons as a part of health-and-wellness care.
- The successful execution of this minimally invasive surgical option for aortic valve replacement, performed at the Cleveland Clinic, underscores the potential of technology in CardioPrecision's vision to revolutionize cardiovascular health by offering less painful procedures, quicker recoveries, and shorter hospital stays.
- As CardioPrecision's robotic AVR procedure gains traction, collaborations with other medical centers like the University of Chicago are being refined, aiming to standardize this technique and bring a new standard of care to the cardiovascular health landscape, integrating it with advanced valve technology and other medical-conditions focused science and technology.
